Centurium Capital Management Ltd., CITIC Capital Partners Management Ltd., Parfield International Ltd., V-Sciences Investments Pte Ltd, Hillhouse Capital Management, Ltd. and Joseph Chow, Chairman and Chief Executive Officer of China Biologic Products Holdings, Inc. entered into a definitive Agreement and Plan of Merger to acquire remaining 31.16% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) for $1.6 billion on November 19, 2020. Under the terms, buyers will pay $120 in cash. The buyers intend to fund the transaction through a combination of (i) rollover equity contributions, (ii) debt financing provided by one or more third party financial institutions, (iii) available cash of the Company and its subsidiaries, and (iv) if any of the PW Medtech Group Share Sales and Parfield Share Sale fails to consummate prior to the closing of the Merger, cash contributions by each of Biomedical Treasure, Biomedical Future and 2019B Cayman and/or their respective affiliates. Sponsors planned to provide equity financing in an aggregate amount of up to approximately US$674.5 million to Parent to complete the merger. Biomedical Treasure will provide $450 million, CCC Co-Investment will provide $145.2 million and $80 million by Biomedical Future. Pursuant to the Merger Agreement and the Plan of Merger, at the effective time of the Merger, CBPO Group will merge with and into the China Biologic Products Holdings, Inc, with the Company continuing as the surviving company and a wholly-owned subsidiary of CBPO Holdings Limited. If consummated, the Merger would result in the China If Consummated, the merger would result in the China Biologic Products Holdings becoming privately held company and its ordinary shares would no longer be listed on the Nasdaq Global Select Market Buyer Consortium will continue to do business under the name “China Biologic Products Holdings, Inc. It is anticipated that the executive officers of the Company will hold positions with the surviving company that are substantially similar to their current positions. Sell side termination fee is $36.36 million and buy side termination fee is $68.31 million. The China Biologic Products board of directors acting upon the unanimous recommendation of a special committee of the Board, composed entirely of independent directors unrelated to the management of the Company or the buyer group, authorized and approved the Merger Agreement on November 19, 2020. Transaction is subject to approval from shareholders of China Biologic and the aggregate number of dissenting shares shall be less than 8% of the total outstanding shares. Special committee of China Biologic unanimously approved the transaction. The special committee of China Biologic Products Holdings, Inc. recommended the shareholders to vote in favor of the transaction. Board of Directors of China Biologic approved the transaction. China Biologic Products announced that it has called an extraordinary general meeting of shareholders to be held on March 1, 2021. The transaction has been approved by the shareholders of China Biologic Products Holdings, Inc., in an extraordinary general meeting held on March 1, 2021. Transaction is expected to complete during the first half of 2021. Duff & Phelps, LLC and Duff & Phelps Securities, LLC acted as financial advisors and Howard Zhang, Yunpeng Fan, Jie Zhang and Mo Zhou of Davis Polk & Wardwell LLP and Maples and Calder (Hong Kong) LLP acted as legal advisors for Special committee of China Biologic. Gary Li, Sarkis Jebejian, Xiaoxi Lin, Julia Yu, Pierre-Luc Arsenault, Joey Chau, Jacqueline Zheng, Justin Dolling, Jennifer Feng, Joshua Korff, Ben James, Matthew Solum, Michael Beinus, Devin Heckman, Cori Lable and James Jian Hu of Kirkland & Ellis LLP, Wilson Sonsini Goodrich & Rosati, P.C., Chen & Associates (in association with Wilson Sonsini Goodrich & Rosati, Professional Corporation), Harney Westwood & Riegels and Fangda Partners acted as legal advisors for buyers. Tim Gardner of Weil, Gotshal & Manges LLP acted as legal advisor to China Biologic Products Holdings, Inc. Weil, Gotshal & Manges LLP acted as legal advisor to Hillhouse Capital Management, Ltd. Centurium Capital Management Ltd., CITIC Capital Partners Management Ltd., Parfield International Ltd., V-Sciences Investments Pte Ltd, Hillhouse Capital Management, Ltd. and Joseph Chow, Chairman and Chief Executive Officer of China Biologic Products Holdings, Inc. completed the acquisition of remaining 31.16% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) on April 20, 2021. As a part of transaction, China Biologic Products Holdings, Inc. will cease to be a publicly traded company. China Biologic Products Holdings, Inc. has requested that trading of its Shares on the Nasdaq Global Select Market (“Nasdaq”) be suspended as of the close of trading on April 20, 2021. China Biologic Products Holdings, Inc. as requested that Nasdaq file a Form 25 with the Securities and Exchange Commission (the “SEC”) notifying the SEC of the delisting of the Shares on Nasdaq and the deregistration of the Company’s registered securities. The deregistration will become effective 90 days after the filing of the Form 25 or such shorter period as may be determined by the SEC. The Company intends to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended, by filing a Form 15 with the SEC in approximately ten days following the filing of the Form 25. The Company’s obligations to file with the SEC certain reports and forms, including Form 20-F and Form 6-K, will be suspended immediately as of the filing date of the Form 15 and will terminate once the deregistration becomes effective.